You are here

Controlled-Release Oxycodone/Acetaminophen Combo Gets Priority Review Status

Indication sought for treatment of acute pain (July 29)

The FDA has accepted a new drug application (NDA) for MNK-795 (Depomed/Mallinckrodt), a controlled-release oral formulation of oxycodone and acetaminophen that has been studied for the management of moderate-to-severe acute pain where the use of an opioid analgesic is appropriate.

The FDA granted the NDA a priority review, a designation given to drugs that, if approved, offer significant improvements in the safety or effectiveness of the treatment when compared with standard applications.

MNK-795 is a reformulation of existing controlled-substance analgesic combination products (oxycodone and acetaminophen) that may be indicated for moderate-to-severe acute pain. According to the compound’s developer (Mallinckrodt), MNK-795 was formulated as a low-dose product to meet an unmet clinical need in the market and also has certain abuse-deterrent characteristics.

Source: Depomed, Inc.; July 29, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs